Insight Molecular Diagnostics (IMDX) Other financing activities (2015 - 2022)

Insight Molecular Diagnostics has reported Other financing activities for 8 years, with the latest figure at $31000.0 in Q1 2022.

• Quarterly Other financing activities fell 99.54% year-over-year to $31000.0 in Q1 2022, while the trailing twelve-month figure through Mar 2022 was -$4.1 million (down 150.35% YoY) and the FY2021 annual result came in at $2.6 million, up 82.08% from the prior year.
• Other financing activities fell to $31000.0 in Q1 2022 per IMDX's latest filing, from $58000.0 in the prior quarter.
• Over five years, Other financing activities peaked at $6.8 million in Q1 2021 and troughed at -$5.9 million in Q2 2021.
• A 5-year average of $503600.0 and a median of $54500.0 in 2018 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2018 and 2019: Other financing activities tumbled 99.97% in 2018, then soared 1749.02% in 2019.
• Over 5 years, Other financing activities stood at $2000.0 in 2018, then soared by 47050.0% to $943000.0 in 2019, then soared by 45.6% to $1.4 million in 2020, then slumped by 95.78% to $58000.0 in 2021, then plunged by 46.55% to $31000.0 in 2022.
• According to Business Quant data, Other financing activities over the past three periods registered $31000.0, $58000.0, and $1.8 million for Q1 2022, Q4 2021, and Q3 2021 respectively.